Science Advances · 2022 · 54 citations · 40 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyImmunopathologyInflammationComplement RegulationComplement SystemComplement System PharmacologyComplement-mediated InjuryComplement-targeted TherapyC3 Complement LevelsC3 ConvertaseComplement In Disease PathogenesisComplement Therapeutic SafetyComplement TherapeuticsComplement-mediated ActivationSafety Of Complement InhibitorsSupplemental Oxygen Therapy
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 ( n = 16) or placebo ( n = 15) in addition to standard of care. AMY-101 was safe and well tolerated. Compared to placebo (8 of 15, 53.3%), a higher, albeit nonsignificant, proportion of AMY-101–treated patients (13 of 16, 81.3%) were free of supplemental oxygen at day 14. Three nonresponders and two placebo-treated patients succumbed to disease-related complications. AMY-101 significantly reduced CRP and ferritin and restrained thrombin and NET generation. Complete and sustained C3 inhibition was observed in all responders. Residual C3 activity in the three nonresponders suggested the presence of a convertase-independent C3 activation pathway overriding the drug’s inhibitory activity. These findings support the design of larger trials exploring the potential of C3-based inhibition in COVID-19 or other complement-mediated diseases.
40
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
Shaobo Shi, Mu Qin, Bo Shen et al. · JAMA Cardiology · 2020 · 4.5K citations · Full text
Diverse functional autoantibodies in patients with COVID-19
Eric Y. Wang, Tianyang Mao, Jon Klein et al. · Nature · 2021 · 984 citations · Full text